AKBA News and Press, Akebia Therapeutics Inc.

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference PR Newswire CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to b...

2024-05-09 11:57:22 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Akebia Therapeutics (NASDAQ: AKBA ) just reported results for the first quarter of 2024. Akebia Therapeutics reported earnings per share of -9 cents. This was below the an...

2024-05-09 10:54:12 ET Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Conference Call May 09, 2024, 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Corporate Communications and IR John Butler - President and Chief Executive Officer Nichola...

2024-05-09 10:00:35 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...

2024-05-09 07:21:26 ET More on Akebia Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade) Akebia Q1 2024 Earnings Preview Akebia stock jumps as FDA clears renal anemia ...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-08 11:42:17 ET More on Akebia Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade) Akebia stock jumps as FDA clears renal anemia therapy Akebia GAAP EPS of $0.00...

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call on May 9, 2024 , at 8:00 a.m. ET CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- Akebia Therapeutics ...

2024-04-04 17:56:46 ET Summary Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient population. The company's other FDA-approved drug, Auryxia,...

2024-04-02 06:16:12 ET Summary Akebia's Vafseo, a HIF-PH inhibitor for DD-CKD anemia, faces skepticism despite FDA approval due to safety concerns. Market skepticism towards HIF-PH inhibitors, evidenced by GSK's hesitance in Europe, suggests limited adoption for Vafseo. Akebia...